LifeMD Crecimiento futuro
Future controles de criterios 2/6
LifeMD is forecast to grow earnings and revenue by 91.1% and 20.1% per annum respectively while EPS is expected to grow by 88.3% per annum.
Información clave
91.1%
Tasa de crecimiento de los beneficios
88.3%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Healthcare Services | 30.6% |
Tasa de crecimiento de los ingresos | 20.1% |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Good |
Última actualización | 14 Oct 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
LifeMD: Are The Commons Too Cheap?
Sep 23LifeMD: Selling WorkSimpli Could Be A Catalyst
Sep 10It's Down 27% But LifeMD, Inc. (NASDAQ:LFMD) Could Be Riskier Than It Looks
Aug 16LifeMD: High Growth GLP-1 Telehealth Play At A Discount
Jul 31LifeMD: Pairing GLP-1 Agonists With Virtual Healthcare
Jun 11LifeMD: Moving Towards Profitability
May 22Is LifeMD (NASDAQ:LFMD) Using Debt Sensibly?
Apr 25Even With A 29% Surge, Cautious Investors Are Not Rewarding LifeMD, Inc.'s (NASDAQ:LFMD) Performance Completely
Mar 30LifeMD: Results And Guidance Point To Continued Strength In Weight Management Program
Mar 13LifeMD's 2024: Striking A Balance Between Rapid Expansion And Sustainability
Jan 22LifeMD: A GLP-1 Play With A Kicker
Jan 11Is LifeMD, Inc. (NASDAQ:LFMD) Potentially Undervalued?
Jan 05Take Care Before Jumping Onto LifeMD, Inc. (NASDAQ:LFMD) Even Though It's 34% Cheaper
Jan 05Does This Valuation Of LifeMD, Inc. (NASDAQ:LFMD) Imply Investors Are Overpaying?
Dec 03Investors Still Aren't Entirely Convinced By LifeMD, Inc.'s (NASDAQ:LFMD) Revenues Despite 38% Price Jump
Apr 17Analysts Are Betting On LifeMD, Inc. (NASDAQ:LFMD) With A Big Upgrade This Week
Nov 17LifeMD launches at-home screening kits for breast, colon cancers
Sep 14LifeMD Non-GAAP EPS of -$0.22 beats by $0.01, revenue of $30.5M misses by $1.45M
Aug 11LifeMD CEO Justin Schreiber - Disrupting Healthcare With Telemedicine
Jan 10Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2026 | 294 | -2 | N/A | N/A | 4 |
12/31/2025 | 255 | -2 | 13 | 39 | 7 |
12/31/2024 | 206 | -22 | 7 | 23 | 7 |
6/30/2024 | 178 | -27 | 7 | 17 | N/A |
3/31/2024 | 164 | -26 | 8 | 17 | N/A |
12/31/2023 | 153 | -24 | 0 | 9 | N/A |
9/30/2023 | 136 | -32 | -7 | 1 | N/A |
6/30/2023 | 129 | -33 | -11 | -3 | N/A |
3/31/2023 | 123 | -39 | -26 | -17 | N/A |
12/31/2022 | 119 | -49 | -36 | -23 | N/A |
9/30/2022 | 118 | -55 | -39 | -27 | N/A |
6/30/2022 | 112 | -61 | -43 | -31 | N/A |
3/31/2022 | 104 | -64 | -42 | -32 | N/A |
12/31/2021 | 93 | -62 | -36 | -33 | N/A |
9/30/2021 | 78 | -75 | -36 | -34 | N/A |
6/30/2021 | 64 | -85 | -32 | -31 | N/A |
3/31/2021 | 51 | -73 | -22 | -22 | N/A |
12/31/2020 | 37 | -63 | -13 | -12 | N/A |
9/30/2020 | 28 | -32 | -6 | -5 | N/A |
6/30/2020 | 20 | -9 | -1 | -1 | N/A |
3/31/2020 | 14 | -5 | 0 | 0 | N/A |
12/31/2019 | 12 | -3 | 0 | 0 | N/A |
9/30/2019 | 11 | -3 | 0 | 0 | N/A |
6/30/2019 | 10 | -3 | 0 | 0 | N/A |
3/31/2019 | 9 | -3 | -1 | 0 | N/A |
12/31/2018 | 8 | -2 | -1 | -1 | N/A |
9/30/2018 | 6 | -2 | -1 | -1 | N/A |
6/30/2018 | 6 | -2 | -1 | -1 | N/A |
3/31/2018 | 5 | -1 | N/A | 0 | N/A |
12/31/2017 | 4 | -1 | N/A | -1 | N/A |
9/30/2017 | 5 | -2 | N/A | -1 | N/A |
6/30/2017 | 3 | -1 | N/A | -1 | N/A |
3/31/2017 | 4 | -2 | N/A | -1 | N/A |
12/31/2016 | 5 | -1 | N/A | 0 | N/A |
9/30/2016 | 5 | -1 | N/A | 0 | N/A |
6/30/2016 | 4 | 0 | N/A | 0 | N/A |
3/31/2016 | 3 | 0 | N/A | 0 | N/A |
12/31/2015 | 1 | 0 | N/A | 0 | N/A |
9/30/2015 | 1 | 0 | N/A | 0 | N/A |
6/30/2015 | 1 | 0 | N/A | 0 | N/A |
3/31/2015 | 1 | 0 | N/A | 0 | N/A |
12/31/2014 | 1 | 0 | N/A | 0 | N/A |
9/30/2014 | 1 | 0 | N/A | 0 | N/A |
6/30/2014 | 1 | 0 | N/A | 0 | N/A |
3/31/2014 | 1 | 0 | N/A | 0 | N/A |
12/31/2013 | 1 | 0 | N/A | 0 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: LFMD is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: LFMD is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: LFMD is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: LFMD's revenue (20.1% per year) is forecast to grow faster than the US market (8.9% per year).
Ingresos de alto crecimiento: LFMD's revenue (20.1% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if LFMD's Return on Equity is forecast to be high in 3 years time